How SV-seeded Alchemab is searching for mAbs in super responders

Alchemab is mining the B cell repertoires of super responders, a strategy used for discovering potent mAbs to treat infectious diseases, and applying the same principle to difficult-to-treat cancer and neurodegeneration. 

An international syndicate of VCs led by RA Capital has bought into the strategy through a £60 million ($82.4 million) series A round. The deal is the second-largest European series A round this year —after NewAmsterdam Pharma B.V.’s $196 million round — and in the top 10 for largest European A rounds since BioCentury’s BCIQ began tracking financings in 1994...